Boston Scientific Corporation $BSX Stock Position Trimmed by HWG Holdings LP

HWG Holdings LP trimmed its position in shares of Boston Scientific Corporation (NYSE:BSX) by 40.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 34,934 shares of the medical equipment provider’s stock after selling 23,641 shares during the period. Boston Scientific accounts for approximately 0.8% of HWG Holdings LP’s holdings, making the stock its 20th biggest position. HWG Holdings LP’s holdings in Boston Scientific were worth $3,331,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $2,089,937,000. Edgewood Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth approximately $746,655,000. Parnassus Investments LLC grew its holdings in Boston Scientific by 42,978.9% in the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after buying an additional 6,868,459 shares in the last quarter. Egerton Capital UK LLP grew its holdings in Boston Scientific by 223.7% in the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after buying an additional 3,671,548 shares in the last quarter. Finally, Jennison Associates LLC increased its position in Boston Scientific by 133.5% in the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after acquiring an additional 2,823,744 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $69.70 on Thursday. Boston Scientific Corporation has a 1 year low of $67.56 and a 1 year high of $109.50. The firm has a market cap of $103.59 billion, a P/E ratio of 35.93, a PEG ratio of 1.05 and a beta of 0.69. The stock has a fifty day moving average price of $78.22 and a two-hundred day moving average price of $91.25. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analyst support: TD Cowen highlighted strong early adoption of BSX’s Agent DCB and kept a Buy rating with a $100 price target, underpinning bullish investor sentiment on multi-year growth potential. Boston Scientific’s Agent DCB: Strong Early Adoption and Underappreciated Multiyear Growth Opportunity
• Positive Sentiment: Potential rating upgrade / turnaround view: A Seeking Alpha piece argues BSX is “under pressure but could see a shift in fortunes,” suggesting a rating upgrade could help sentiment if upcoming operational data improves. Boston Scientific: Under Pressure, But Could See A Shift In Fortunes (Rating Upgrade)
• Positive Sentiment: Bullish “buy the dip” narratives: MarketBeat and other bullish write-ups view the recent pullback as an opportunity tied to pending trial results and long-term device adoption, supporting short-term buying interest. Why Boston Scientific’s Big Dip Could Be a Bigger Opportunity
• Neutral Sentiment: Industry note (unrelated company): Stratus Medical was named to Fortune’s Most Innovative Companies list — a positive for the RFA/chronic pain segment but not directly tied to BSX results. Investors may view it as a sector-level signal rather than company-specific news. Stratus Medical Recognized on Fortune’s America’s Most Innovative Companies List for 2026
• Negative Sentiment: Surge of securities-law firm notices and class-action filings allege misstatements around U.S. electrophysiology volumes; multiple firms (Bronstein, Faruqi, Levi & Korsinsky, Pomerantz, Rosen, Robbins, Bernstein Liebhard, etc.) are soliciting lead-plaintiff candidates and reminders about the May 4, 2026 deadline—heightening litigation risk and headline volatility for BSX. Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm BSX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Boston Scientific Investors of Securities Class Action Deadline on May 4, 2026
• Negative Sentiment: Recent stock weakness and volatility: News outlets and Zacks noted BSX shares have recently traded down more sharply than the broader market, reflecting investor concern over guidance, electrophysiology volumes, and litigation headlines. Boston Scientific (BSX) Falls More Steeply Than Broader Market: What Investors Need to Know

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Royal Bank Of Canada reduced their price target on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Needham & Company LLC reissued a “buy” rating and set a $97.00 price target on shares of Boston Scientific in a report on Friday, March 20th. Truist Financial cut their price objective on shares of Boston Scientific from $95.00 to $92.00 and set a “buy” rating on the stock in a research note on Wednesday, March 18th. Evercore reduced their price objective on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Boston Scientific in a research report on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Buy” and an average price target of $106.27.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.